Jingfeng Zhou

787 total citations
22 papers, 609 citations indexed

About

Jingfeng Zhou is a scholar working on Molecular Biology, Hematology and Ophthalmology. According to data from OpenAlex, Jingfeng Zhou has authored 22 papers receiving a total of 609 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Hematology and 7 papers in Ophthalmology. Recurrent topics in Jingfeng Zhou's work include Chronic Myeloid Leukemia Treatments (7 papers), Ocular Oncology and Treatments (7 papers) and Acute Myeloid Leukemia Research (3 papers). Jingfeng Zhou is often cited by papers focused on Chronic Myeloid Leukemia Treatments (7 papers), Ocular Oncology and Treatments (7 papers) and Acute Myeloid Leukemia Research (3 papers). Jingfeng Zhou collaborates with scholars based in China, United States and South Korea. Jingfeng Zhou's co-authors include Jingxuan Pan, Bei Jin, Yanli Jin, Wei Dai, Xin Du, Yangqiu Li, Yun Wang, Yun Wang, Peng Li and Juan Li and has published in prestigious journals such as Journal of Clinical Investigation, Cancer Research and Scientific Reports.

In The Last Decade

Jingfeng Zhou

19 papers receiving 604 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jingfeng Zhou China 13 411 129 100 80 76 22 609
Francesca Alvarez‐Calderon United States 9 239 0.6× 65 0.5× 141 1.4× 45 0.6× 47 0.6× 12 438
April Reed United States 12 535 1.3× 224 1.7× 30 0.3× 39 0.5× 40 0.5× 15 677
A Yen United States 13 323 0.8× 109 0.8× 63 0.6× 24 0.3× 82 1.1× 19 450
Marie‐France Gaumont‐Leclerc Canada 10 668 1.6× 247 1.9× 71 0.7× 11 0.1× 122 1.6× 11 883
Marco Cirò Italy 10 859 2.1× 320 2.5× 77 0.8× 22 0.3× 83 1.1× 11 1.1k
Adonia E. Papathanassiu United States 8 275 0.7× 48 0.4× 157 1.6× 9 0.1× 110 1.4× 14 552
Tiziana Tonini United States 11 431 1.0× 229 1.8× 12 0.1× 33 0.4× 58 0.8× 15 646
Dayanand Deo United States 8 318 0.8× 242 1.9× 29 0.3× 8 0.1× 54 0.7× 15 537
Miriam Canavese United States 10 674 1.6× 398 3.1× 168 1.7× 8 0.1× 125 1.6× 21 923
Neil MacLean Canada 17 588 1.4× 253 2.0× 167 1.7× 6 0.1× 92 1.2× 38 816

Countries citing papers authored by Jingfeng Zhou

Since Specialization
Citations

This map shows the geographic impact of Jingfeng Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingfeng Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingfeng Zhou more than expected).

Fields of papers citing papers by Jingfeng Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingfeng Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingfeng Zhou. The network helps show where Jingfeng Zhou may publish in the future.

Co-authorship network of co-authors of Jingfeng Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Jingfeng Zhou. A scholar is included among the top collaborators of Jingfeng Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingfeng Zhou. Jingfeng Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Zhenghao, Keming Li, Zhe Yu, et al.. (2025). Targeting PRDX1 impairs acute myeloid leukemic blasts and stem cells by disrupting redox homeostasis. Cell Death and Disease. 16(1). 627–627.
2.
Pei, Han Zhong, Yuming Zhao, Zhiguang Chang, et al.. (2025). FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia. Cancer Letters. 611. 217446–217446. 3 indexed citations
3.
4.
Liu, Ying, Yanli Zhao, Zhicheng Gong, et al.. (2025). USP5 inhibition enables potential therapy for t(8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenografts. Science Translational Medicine. 17(817). eadt9100–eadt9100.
5.
Zhou, Jingfeng, Danian Nie, Peilong Lai, et al.. (2021). Super-enhancer landscape reveals leukemia stem cell reliance on X-box binding protein 1 as a therapeutic vulnerability. Science Translational Medicine. 13(612). eabh3462–eabh3462. 22 indexed citations
6.
Zhou, Jingfeng, Shenglan Liu, Yun Wang, et al.. (2021). Correction to: Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma. Molecular Cancer. 20(1). 47–47. 2 indexed citations
7.
Dai, Wei, Shenglan Liu, Li Zhao, et al.. (2021). Activation of transmembrane receptor tyrosine kinase DDR1-STAT3 cascade by extracellular matrix remodeling promotes liver metastatic colonization in uveal melanoma. Signal Transduction and Targeted Therapy. 6(1). 176–176. 44 indexed citations
8.
Zhou, Jingfeng, et al.. (2020). Rapid Analysis of Four Amphetamines in Urine by Self-Made Pipette-Tip Solid-Phase Extraction Followed by GC-MS/MS. Journal of Chromatographic Science. 58(6). 569–575. 8 indexed citations
9.
Zhou, Jingfeng, Shenglan Liu, Yun Wang, et al.. (2019). Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma. Molecular Cancer. 18(1). 159–159. 49 indexed citations
10.
Gupta, Pranav, Guan-Nan Zhang, Xin Zhang, et al.. (2019). Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia. Cancer Letters. 472. 132–141. 13 indexed citations
11.
Liu, Chang, Danian Nie, Juan Li, et al.. (2018). Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells. Cancer Research. 78(6). 1522–1536. 26 indexed citations
12.
Zhou, Jingfeng, Danian Nie, Juan Li, et al.. (2017). PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia. Clinical Cancer Research. 24(1). 145–157. 27 indexed citations
13.
Jin, Yanli, Ping Zhang, Yun Wang, et al.. (2017). Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma. Clinical Cancer Research. 24(15). 3741–3754. 48 indexed citations
14.
Zhou, Jingfeng, Bei Jin, Yanli Jin, Yizhi Liu, & Jingxuan Pan. (2017). The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo. Theranostics. 7(6). 1447–1462. 55 indexed citations
15.
Jin, Yanli, Jingfeng Zhou, Fang Xu, et al.. (2016). Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. Journal of Clinical Investigation. 126(10). 3961–3980. 135 indexed citations
16.
Jin, Yanli, Danian Nie, Juan Li, et al.. (2016). Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin. Clinical Cancer Research. 23(11). 2842–2855. 37 indexed citations
17.
Dai, Wei, Jingfeng Zhou, Bei Jin, & Jingxuan Pan. (2016). Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. Scientific Reports. 6(1). 22622–22622. 70 indexed citations
18.
Zhou, Jingfeng, et al.. (2014). Study on Chemical Constituents of Cinnamomum Camphora Leaves. Tianran chanwu yanjiu yu kaifa. 26(11). 1793. 5 indexed citations
19.
Fei, Zhaoliang, Liang Xiao, Jingfeng Zhou, et al.. (2012). mBin1b transgenic mice show enhanced resistance to epididymal infection by bacteria challenge. Genes and Immunity. 13(6). 445–451. 23 indexed citations
20.
Wei, Xiange, et al.. (2007). Forms and balance of nitrogen and phosphorus in cage culture waters in Guangdong Province, China. Chinese Geographical Science. 17(4). 370–375. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Alvarez‐Calderon Breakdown of academic impact, for papers by April Reed Breakdown of academic impact, for papers by A Yen Breakdown of academic impact, for papers by Marie‐France Gaumont‐Leclerc Breakdown of academic impact, for papers by Marco Cirò Breakdown of academic impact, for papers by Adonia E. Papathanassiu Breakdown of academic impact, for papers by Tiziana Tonini Breakdown of academic impact, for papers by Dayanand Deo Breakdown of academic impact, for papers by Miriam Canavese Breakdown of academic impact, for papers by Neil MacLean
Rankless by CCL
2026